Avectas Scientific Advisory Board
Avectas SAB Meeting was held in London, UK on November 16th 2018. The Senior Avectas Management Team was joined by Scientific Advisory Board Chair, Prof. Mark Lowdell, in hosting the following newly appointed members;
- Prof. Bruce L. Levine
- Dr. Evren Alici
- Dr. Karl Peggs
Avectas look forward working closely with the Scientific Advisory Board to further develop the Avectas Technology, Solupore®. Further details about the board members appointments and experience can be found here.
Maynooth team secures €2.1m EU funding for cancer therapy
Avectas, an Irish company developing cutting-edge technology to help cure cancers, has secured €2.1 million funding under the European Union’s Horizon 2020 programme. The Maynooth-based biotech is the only Irish company to be awarded funding in the current round of Horizon 2020 – the EU Framework Programme for Research and Innovation. Avectas is developing a technology that temporarily makes permeable cells extracted from a patient and allows them to be re-engineered to attack cancers before being infused back into patients. Its approach addresses two key challenges in the immunotherapy approach to tackling the disease – the reliance on viruses to help re-engineer cells and the length of the costly cell engineering process. Under current immunotherapy approaches, pharma companies can wait for years for the required virus to become available. The subsequent cell engineering process can take up to 22 days. The Avectas permubalisation approach does away with the need for viruses and reduces the time involved in the cell engineering process.
Read more: The Irish Times March 20th 2018
Read more: The Irish Times April 5th 2018
Avectas Ltd., to Present at the Biotech Showcase™ Annual Conference on January 8th, 2018
Dublin, 02/01/2017 – Avectas, a biotechnology company, developing a novel vector-free cell engineering technology today announced it will present a corporate overview at Biotech Showcase 2018, during the course of one of the industry's largest annual healthcare investor meetings, J.P. Morgan Annual Healthcare Conference, in San Francisco on January 8th.
Dr. Michael Maguire, CEO will present at the Biotech Showcase™ as follows:
Date: Monday, January 8th, 2018
Time: 2.00 pm (PST)
Room: Franciscan - C (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
Our ambition is to be the market leading vector-free delivery technology for next-generation cell and gene therapies. Avectas is a biotechnology company developing Solupore®, a novel vector-free cell engineering technology addressing challenges in intracellular delivery and manufacturing in the immuno-oncology space including CAR-T and gene editing.
About the Biotech Showcase™:
The Biotech Showcase™ produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to private and public biotechnology and life sciences companies during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that Avectas will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”
Director of Business Development
More information: www.avectas.com
Additional links and information:
Follow Avectas on Twitter: @Avectas
Follow Biotech Showcase on Twitter: @EBDGroup and @Demy_Colton - #BiotechShowcase